Literature DB >> 23583133

Sacrococcygeal yolk sac tumor developing after teratoma: a clinicopathological study of pediatric sacrococcygeal germ cell tumors and a proposal of the pathogenesis of sacrococcygeal yolk sac tumors.

Mariko Yoshida1, Kentaro Matsuoka, Atsuko Nakazawa, Makiko Yoshida, Takeshi Inoue, Hiroshi Kishimoto, Masahiro Nakayama, Emi Takaba, Minoru Hamazaki, Shigeaki Yokoyama, Hiroshi Horie, Mio Tanaka, Kiyoshi Gomi, Youkatsu Ohama, Hisato Kigasawa, Yoshihiro Kitano, Hiroo Uchida, Yutaka Kanamori, Tadashi Iwanaka, Yukichi Tanaka.   

Abstract

PURPOSE: We evaluated the clinicopathological characteristics of pediatric sacrococcygeal germ cell tumors (SGCTs) and yolk sac tumors (YSTs) developing after sacrococcygeal teratoma (SCT) resection, and discussed the pathogenesis of sacrococcygeal YST.
METHODS: We retrospectively analyzed pediatric SGCT patients attending 10 Japanese institutions.
RESULTS: A total of 289 patients were eligible, of which 74.6% were girls. The mean age at surgery was 7.1months. There were 194 mature and 47 immature teratomas, and 48 YSTs. YST developed after SCT resection in 13 patients (5.4% of SCTs), and was detected between 5 and 30months after resection. At initial surgery, 9 of these 13 patients were neonates, 12 underwent gross complete resection with coccygectomy, and 9 had histologically mature teratoma without microscopic YST foci. Postoperative serum alpha-fetoprotein (AFP) levels were regularly examined in 11 patients. Intervals of AFP measurement≤4months helped to detect subclinical localized YSTs for resection.
CONCLUSIONS: The characteristics of SGCT in Japanese children were similar with those reported in Europe or the United States. YST developed after SCT resection not only in patients with previously reported risk factors. We recommend that patients undergo serum AFP monitoring every 3months for≥3years after SCT resection.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23583133     DOI: 10.1016/j.jpedsurg.2012.08.028

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  Primary juxtaovarian yolk sac tumor concurrent with an ipsilateral ovarian mature teratoma in an adult woman: a rare association.

Authors:  Haifen Ma; Jihong Yu; Jingjing Tang; Min Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Evaluation of chemotherapeutic sequelae and quality of life in survivors of malignant sacrococcygeal teratoma.

Authors:  Marijke E B Kremer; Joep P M Derikx; Leontien C M Kremer; Robertine van Baren; Hugo A Heij; Marc H W A Wijnen; René M H Wijnen; David C van der Zee; L W Ernest van Heurn
Journal:  Pediatr Surg Int       Date:  2015-12-14       Impact factor: 1.827

3.  Malignant sacrococcygeal germ cell tumors in children in Taiwan: A retrospective single-center case series.

Authors:  Shih-Hsiang Chen; Chia-Jui Du; Jin-Yao Lai; Tsung-Yen Chang; Chao-Ping Yang; Iou-Jih Hung; Tang-Her Jaing; Yung-Ching Ming; Chuen Hsueh
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

4.  Case Reports: Management Challenges in Pediatric Germ Cell Tumors.

Authors:  Sophie Carr; Arash Safavi; Erik D Skarsgard
Journal:  Front Pediatr       Date:  2021-04-15       Impact factor: 3.418

5.  Multimodal Treatment of Children With Sacrococcygeal Yolk Sac Tumor: Retrospective Analysis of Clinicopathology Characteristics and Relapse-free Survival.

Authors:  Jia Zhu; Huadong Chen; Tingting Chen; Zijun Zhen; Juan Wang; Feifei Sun; Suying Lu; Junting Huang; Yizhuo Zhang; Xiaofei Sun
Journal:  J Pediatr Hematol Oncol       Date:  2021-01-27       Impact factor: 1.289

Review 6.  Pure yolk sac tumor of sacrococcygeal region.

Authors:  Rashim Sharma; Sudeep Khera; Arvind Sinha; Taruna Yadav
Journal:  Autops Case Rep       Date:  2021-05-25

Review 7.  Intracranial Germ Cell Tumor in the Molecular Era.

Authors:  Ji Hoon Phi; Kyu-Chang Wang; Seung-Ki Kim
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.